Agilent Technologies' Cancer Test Gets Expanded Approval From FDA
By Kelly Cloonan
Agilent Technologies got approval to expand the use of a cancer test to additional tumor types from the Food and Drug Administration.
The laboratory technologies company said Tuesday the FDA approved PD-L1 testing for use on the Dako Omnis platform, a technology used to diagnose diseases, to help identify patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer and gastric or gastroesophageal junction who may be eligible for treatment with Keytruda.
The approval expands access to PD-L1 testing to four additional tumor types, adding to previous approvals for non-small cell lung cancer and head and neck squamous cell carcinoma. Those initial approved indications were only available on the Autostainer Link 48 platform and are now also approved for the Dako Omnis platform, allowing labs to consolidate testing across more tumor types within a single Dako Omnis workflow, the company said.
PD-L1 was developed by Agilent in partnership with Merck as a companion diagnostic for Merck's Keytruda.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
June 02, 2026 16:58 ET (20:58 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States